Head and Neck, Esophageal Medical Oncology (formerly Head and Neck Medical Oncology)

Introduction

The Department of Head and Neck, Esophageal Medical Oncology focuses on the development of new drugs and establishment of standard chemotherapy regimens, including multimodality treatment with surgery and/or radiotherapy for advanced head and neck cancers (HNCs), consisting of malignancies arising from the oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, nasal/paranasal cavity, salivary gland, ear canal, thyroid and so on. We also focus on the multimodality treatment of esophageal cancer (EC), mainly chemotherapy and chemoradiotherapy. The main histology of HNC and EC is squamous cell carcinoma. However, there is still a wide variety of histological types, especially in the nasal/paranasal cavity, salivary glands, and gastroesophageal-junctional cancer. Therefore, pathological diagnosis is essential, making a treatment strategy based on pathological findings significant in advanced HNCs and ECs.

The Team and What We Do

The staff of the Department of Head and Neck, Esophageal Medical Oncology consists of 4 medical oncologists. We hold a daily case conference together and also hold a monthly research conference and discuss the progress of clinical trials or in-house research. Intergroup meetings with the Departments of Head and Neck Surgery, Esophageal Surgery, Endoscopy, Radiation Oncology, Diagnostic Radiology, and Diagnostic Pathology are held weekly to decide optimal treatment strategies for each individual case and to discuss treatment consensus for the disease. In 2022, we treated 465 new patients, including 293 with esophagus/esophagogastric junction cancer and 175 with head and neck cancer. Rare cancers of the head and neck region, such as undifferentiated thyroid cancer and salivary gland cancer, have also been treated through referrals from other hospitals. Of these patients, 65 were entered into clinical trials.

Research activities

A trans-oral/percutaneous biopsy and blood sampling before and after cetuximab and nivolumab provide an excellent opportunity to study biomarkers. We are collecting these fresh samples from patients with HNSCC to evaluate the correlations between gene expression or immunogenic profiles and patients’ outcomes by using genome sequencing, immune-panel, microarray, or real-time PCR techniques.

We have also been measuring the gene expressions of possible predictive biomarkers by using FFPE samples obtained from surgical resection or trans-oral/percutaneous biopsy. These studies are being performed in collaboration with the Center for Medical Genomics, National Cancer Center Research Institute (NCCRI), or other institutions.

We have performed an investigator-initiated trial (FRONTiER study) regarding patients with locally resectable esophageal squamous cell carcinoma, to evaluate the safety and efficacy of neoadjuvant chemotherapy with nivolumab. Along with this multicenter trial, biomarker analysis of immunotherapy using biopsy samples, fecal samples and other methods has been conducted with collaborators at NCCRI or other institutions. The results were presented in the ASCO-GI meeting. In addition, the results of a comparative study of preoperative treatment for resectable esophageal cancer (JCOG1109) conducted by Kato at JCOG were presented at the Oral Session at ASCO-GI 2022.

The results of the global CheckMate-648 study (a study demonstrating the add-on effect of nivolumab and the superiority of nivolumab + ipilimumab combination therapy in first-line chemotherapy patients for esophageal cancer) were published in the New England Journal of Medicine. Kato participated as a corresponding author.

Clinical trials

We carried out clinical trials in collaboration with the Departments of Head and Neck Surgery, Esophageal Surgery, Gastrointestinal Endoscopy, Radiation Oncology, Diagnostic Radiology, and Diagnostic Pathology in our hospital. Details of clinical trials are summarized in the Table, including JCOG (Japan Clinical Oncology Group) trials, company-initiated trials, and other collaborative investigator-initiated trials. The list of trials conducted in our department and the number of registrations are shown (Table 1).

Table 1. Clinical trials and the number of registered patients.

Education

Residents and staff make rounds every day and provide on-the-job education. Each staff member conducts lectures for residents every three months, and also distributes them as ZOOM and video archives to facilities with former residents and related facilities. Residents made 24 presentations in Japan and 14 overseas, and published 20 papers in English (5 in oridinal article, 15 in review article) in 2020～2022.

Future Prospects

We are conducting investigator-initiated clinical trials to examine the usefulness of nivolumab in preoperative treatment for esophageal cancer, and we have also enrolled a large number of patients in investigator-initiated clinical trials for salivary gland cancer in the field of head and neck cancer. In addition, we are currently discussing with a company about conducting a doctor-initiated clinical trial of a combination therapy of photoimmunotherapy and an immune checkpoint inhibitor. We are also conducting joint research with China on investigator-initiated clinical trials of CDK4/6 inhibitors for esophageal cancer. In addition, we will collaborate with other hospitals using ZOOM.

List of papers published

Journal

1. Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol, 33(9):959-967, 2022
2. Omura G, Honma Y, Matsumoto Y, Shinozaki T, Itoyama M, Eguchi K, Sakai T, Yokoyama K, Watanabe T, Ohara A, Kato K, Yoshimoto S. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma  . Auris Nasus Larynx, S0385-8146(22)00167-5., 2022
3. Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer. Cancer Science, 113(8):2814-2827., 2022
4. Suzuki K, Igata H, Abe M, Yamamoto Y; small RNA based cancer classification project. Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Science, 113(6):2144-2166., 2022
5. Itami J, Kobayashi K, Mori T, Honma Y, Kubo Y, Murakami N, Omura G, Okuma K, Inaba K, Takahashi K, Kashihara T, Shimizu Y, Takahashi A, Nakayama Y, Matsumoto F, Yoshimoto S, Igaki H. Non-robustness of Ang’s risk classification in human papillomavirus-related oropharyngeal squamous cell carcinoma in Japanese patients. Cancers, 14(10):2442., 2022
6. Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res, 28(15):3277-3286., 2022
7. Oguma J, Ishiyama K, Kurita D, Kanematsu K, Fujii Y, Kubo K, Yamamoto S, Honma Y, Kato K, Daiko H. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery. Esophagus, 19(2):214-223., 2022
8. Doki Y, Ajani JA, Kato K Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, Hajbi EF, Bartolomeo MD, Braghiroli MI, Holtved E, Ostoich CA, Kim HR, Ueno M, Mansoor, W, Yang, WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu, X, Lei M, Kondo K, Patel A, Gricar, J., Chau, I, Kitagawa Y. Nivolumab plus Chemotherapy or Ipilimumab in Advanced Esophageal Squamous Cell Carcinoma . New Engl J Med., 386(5):449-462., 2022
9. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus S-1/capecitabine plus oxaliplatin versus placebo plus S 1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable advanced or recurrent HER2-negative gastric/gastroesophageal junction cancer: a multi-centre, randomised, double-blind, phase 3 trial (ATTRACTION-4). Lancet Oncology, 23(2):234-247., 2022
10. Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsuhashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, Yoshino T. Clinical Validity of Plasma-based Genotyping for Microsatellite Instability Assessment in Advanced Gastrointestinal Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncol, e2100383., 2022
11. Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. The role of the EZH2 and H3K27me3 expression as a predictor of clinical outcomes in salivary duct carcinoma patients: A large-series study with emphasis on the relevance to the combined androgen blockade and HER2-targeted therapy. Front Oncol, 11:779882., 2022
12. Kang YK, Morita S, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Chen LT, Boku N. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post-hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer, 25(1):207-217., 2022
13. Kubo Y, Kitagawa Y, Miyazaki T, Sohda M, Yamaji T, Sakai M, Saeki H, Nemoto K, Oyama T, Muto M, Takeuchi H, Toh Y, Matsubara H, Mano M, Kono K, Kato K, Yoshida M, Kawakubo H, Booka E, Yamatsuji T, Kato H, Ito Y, Ishikawa H, Ishihara R, Tsushima T, Kawachi H, Oyama T, Kojima T, Kuribayashi S, Makino T, Matsuda S, Doki Y, Esophageal Cancer Practice Guidelines Preparation Committee. The potential for reducing alcohol consumption to prevent esophageal cancer morbidity in Asian heavy drinkers: a systematic review and meta-analysis. Esophagus, 19(1):39-46., 2022
14. Muro K, Kojima T, Moriwaki T, Kato K, Nagashima F, Kawakami H, Ishihara R, Ogata T, Satoh T, Iwakami K, Han S, Yatsuzuka N, Takami T, Bhagia P, Doi T. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus, 19(1):137-145., 2022
15. Sakai M, Kitagawa Y, Saeki H, Miyazaki T, Yamaji T, Nemoto K, Oyama T, Muto M, Takeuchi H, Toh Y, Matsubara H, Mano M, Kono K, Kato K, Yoshida M, Kawakubo H, Booka E, Yamatsuji T, Kato H, Ito Y, Ishikawa H, Ishihara R, Tsushima T, Kawachi H, Oyama T, Kojima T, Kuribayashi S, Makino T, Matsuda S, Sohda M, Kubo Y, Doki Y; Esophageal Cancer Practice Guidelines Preparation Committee. Fruit and vegetable consumption and risk of esophageal cancer in the Asian region: a systematic review and meta-analysis. Esophagus, 19(1):27-38., 2022
16. Shibayama T, Shimoi T, Mori T, Noguchi E, Honma Y, Hijioka S, Yoshida M, Ogawa C, Yonemori K, Yatabe Y, Yoshida A. Cytokeratin-positive malignant tumor in the abdomen with EWSR1/FUS-CREB fusion: a clinicopathological study of eight cases. Am J Surg Pathol, 46(1): 134-146., 2022
17. Inoue T, Ishihara R, Shibata T, Suzuki K, Kitagawa Y, Miyazaki T, Yamaji T, Nemoto K, Oyama T, Muto M, Takeuchi H, Toh Y, Matsubara H, Mano M, Kono K, Kato K, Yoshida M, Kawakubo H, Booka E, Yamatsuji T, Kato H, Ito Y, Ishikawa H, Tsushima T, Kawachi H, Oyama T, Kojima T, Kuribayashi S, Makino T, Matsuda S, Doki Y; Esophageal Cancer Practice Guidelines Preparation Committee. Endoscopic imaging modalities for diagnosis of invasion depth of superficial esophageal squamous cell carcinoma: a systematic review. Esophagus, 19(3):375-383., 2022
18. Mori Y, Kikuchi O, Horimatsu T, Hara H, Hironaka S, Kojima T, Kato K, Tsushima T, Ishihara R, Mukai K, Uozumi R, Tada H, Kasai H, Kawaguchi A, Muto M. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma　refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus, 19(3):444-451., 2022
19. Takashi Kojimaa, Hiroki Harab, Akihito Tsujic, Hisateru Yasuid, Kei Muroe, Taroh Satohf, Takashi Ogatag, Ryu Ishiharah, Masahiro Gotoi, Hideo Babaj, Tomohiro Nishinak, Shirong Hanl, Tomoko Sakatal, Naoyoshi Yatsuzukal, Toshihiko Doim, Ken Katon. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus, 19(4):683-692., 2022
20. Kojima T, Kato K, Hara F, Takahashi S, Muro K, Nishina T, Wakabayashi M, Nomura S, Sato A, Ohtsu , Doi T. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus, 19(4):702-710., 2022
21. Takemura C, Kashima J, Hashimoto T, Ichikawa H, Honma Y, Goto Y, Watanabe S, Yatabe S. A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma. Histopathology, 80: 1004-1010, 2022
22. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): A randomized Phase 3 study. J Clin Oncol, 40(26):3065-3076., 2022
23. Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y . A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1. Cancer Science, 113(3):1018-1027., 2022
24. Tsubokura M, Adegawa Y, Kojima M, Tanosaki R, Ohtake R, Kase Y, Iwashita N, Kasane M, Nakabayashi S, Takeuchi S, Kato K, Boku N, Kanemitsu Y, Okusaka T, Fujimoto H, Yonemori K, Ishiki H, Kawamura K, Satomi E, Matsushita H. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience. BMC Cancer, 22(1):268., 2022
25. Mitani S, Kato K, Daiko H, Ito Y, Nozaki I, Kojima T, Yano M, Nakagawa S, Ueno M, Watanabe M, Tsunoda S, Abe T, Kadowaki S, Kadota T, Sasaki K, Machida R, Kitagawa Y. Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies. J Gastroenteology, 57(7):455-463., 2022
26. Shimizu Y, Murakami N, Mori T, Takahashi K, Kubo Y, Yoshimoto S, Honma Y, Nakamura S, Okamoto H, Iijima K, Takahashi A, Kaneda T, Kashihara T, Inaba K, Okuma K, Nakayama Y, Igaki H, Itami J. Clinical impact of p16 positivity in nasopharyngeal carcinoma. Laryngoscope Investig Otolaryngol., 7(4):994-1001., 2022
27. Nozaki I, Machida R, Kato K, Daiko H, Ito Y, Kojima T, Yano M, Ueno M, Nakagawa S, Kitagawa Y. Long‑term survival of patients with T1bN0M0 esophageal cancer after thoracoscopic esophagectomy using data from JCOG0502: a prospective multicenter trial. Surg. Endosc, ;36(6):4275-4282., 2022
28. Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Survival Benefit of HER2-targeted or Androgen Deprivation Therapy in Salivary Duct Carcinoma. Ther Adv Med Oncol., 14:1-17., 2022
29. Miyata Y, Murakami N, Honma Y, Mori T, Yoshimoto S, Kashihara T, Takemori M, Nakayama Y, Itami J, Ogo E, Igaki H. A High-Dose-Rate Interstitial Brachytherapy Boost for Residual Sinonasal Undifferentiated Carcinoma. J Radiat Res, 63: 879-883., 2022
30. Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, Mizukami T, Moriwaki T, Ohtsubo K, Komoda M, Mitani S, Nagashima F, Kato K, Yamada T, Hasegawa H, Yamazaki K, Yoshino T, Hyodo I. Association of ERBB2 Copy Number and Gene Co-Alterations with Trastuzumab Efficacy and Resistance in HER2-Positive Esophagogastric and Gastric Cancer. JCO Precision Oncology, e2200135, 2022
31. Tsukamoto S, Honma Y, Kanemitsu Y. Clinical outcomes of surgical and multimodal treatment for rectal gastrointestinal stromal tumours: organ preservation in the imatinib era. BJS Open, 6: zrac07., 2022
32. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K. T-cell–inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncology, 18: 2783-2790., 2022
33. Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S,　Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. A Single-Arm Confirmatory Study of Definitive Chemoradiotherapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys., 114(3):454-462., 2022
34. Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada K, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y. Clinical practice guidelines for Duodenal Cancer 2021. J Gastroenteology, 57: 927-941., 2022
35. Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol, 8(10): 1447-1455., 2022
36. Udagawa C, Kuah S, Shimoi T, Kato K, Yoshida T, Nakano MH, Shimo A, Kojima Y, Yoshie R, Tsugawa K, Mushiroda T, Tan EY, Zembutsu H. Replication Study for the Association of Five SNPs Identified by GWAS and Trastuzumab-Induced Cardiotoxicity in Japanese and Singaporean Cohorts. Biol Pharm Bull, 45(8):1198-1202., 2022
37. Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open, 7(4):100517., 2022
38. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Correction to: Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 and Part 2. Esophagus, 19(4):726., 2022
39. Ida H, Koyama T, Mizuno T, Sunami K, Kubo T, Sudo K, Tao K, Hirata M, Yonemori K, Kato K, Okusaka T, Ohe Y, Matsui Y, Yamazaki N, Ogawa C, Kawai A, Narita Y, Esaki M, Yamamoto N. Clinical Utility of Comprehensive Genomic Profiling Tests for Advanced or Metastatic Solid Tumor in Clinical Practice. Cancer Sci, 113(12):4300-4310. , 2022
40. Kohsaka S, Tada Y, Ando M, Nakaguro M, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, Mano H, Shirai Y. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. NPJ Precis Oncol , 6(1): 82., 2022
41. Shun Yamamoto, Naoki Sakakibara, Hidekazu Hirano, Chigusa Morizane, Yoshitaka Honma, Susumu Hijioka, Takuji Okusaka, Takahiro Higashi, Akira Kawai. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. Sci Rep, 12(1):17601, 2022
42. Miura T, Mitsunaga S, Matsuzaki J, Takizawa S, Kato K, Ochiai A, Ochiya T. Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients. Oncotarget, 13:1341-1349., 2022
43. Suzuki K, Yamaguchi T, Kohda M, Tanaka M, Takemura H, Wakita M, Tabe Y, Kato S, Nasu M, Hashimoto T, Mine S, Serizawa N, Tomishima K, Nagahara A, Matsuda T, Yamaji T, Tsugane S, Saito Y, Daiko H, Yoshikawa T, Kato K, Okusaka T, Ochiya T, Yamamoto Y, Yotsui S, Yamamoto T, Yamasaki T, Miyata H, Yasui M, Omori T, Ohkawa K, Ikezawa K, Nakabori T, Sugimoto N, Kudo T, Yoshida K, Ohue M, Nishizawa T. Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PLoS One, 17(12):e0278927., 2022

Back to NCC Today-Blog